Actively Recruiting

Age: 18Years +
All Genders
ID07229235

REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria: an Observational Study

Led by Novartis Pharmaceuticals · Updated on 2026-05-18

50

Participants Needed

10

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the effectiveness and safety of iptacopan in adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in routine clinical practice. The study focuses on long-term hematological response, transfusion avoidance, and patient-reported outcomes. The main goal is to assess the change in hemoglobin levels and the proportion of patients who avoid red blood cell transfusions during the first year after starting iptacopan. This observational study includes adult patients who are either new to iptacopan treatment or transitioning from a Managed Access Program. Data will be collected retrospectively, prospectively, or as a combination, depending on the patient's treatment history. Patients will be followed for up to 24 months or until iptacopan is discontinued for various reasons. No extra visits or procedures beyond routine care are required, and questionnaires will be collected when possible during scheduled visits. Participants will be monitored through regular clinical assessments without any additional study-imposed visits. Researchers will collect data on hemoglobin levels, transfusion needs, and various laboratory measures over 12 and 24 months. Patient-reported outcomes and safety events will also be tracked. The study aims to gather real-world information on iptacopan's impact in clinical practice, with participation lasting up to two years or until treatment discontinuation.

CONDITIONS

Brief Title

REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed informed consent prior to any study assessment, except for deceased patients as per legal provisions
  • Male or female
  • At least 18 years of age
  • Documented diagnosis of Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • Followed at Italian clinical sites
  • On treatment with iptacopan prescribed as part of routine medical care, either naive to treatment or previously treated under the Managed Access Program (MAP)
Not Eligible

You will not qualify if you...

  • Participation in another interventional clinical study related to PNH or its treatment
  • No other criteria beyond the Summary of Product Characteristics (SmPC) apply

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Monitoring

Duration - Up to 24 months or until iptacopan discontinuation, clinical decision, death, consent withdrawal, or loss to follow-up

Participants who undergo routine care with iptacopan are observed to collect clinical data and complete questionnaires at routine visits whenever possible.

Visits occur as part of routine clinical care; questionnaires are collected at routine visits but no extra visits are scheduled

Trial Site Locations

Total: 10 locations

1

Novartis Investigative Site

Alessandria, AL, Italy, 15121

Actively Recruiting

2

Novartis Investigative Site

Avellino, AV, Italy, 83100

Actively Recruiting

3

Novartis Investigative Site

Brescia, BS, Italy, 25123

Actively Recruiting

4

Novartis Investigative Site

Florence, FI, Italy, 50134

Actively Recruiting

5

Novartis Investigative Site

Milan, MI, Italy, 20132

Actively Recruiting

6

Novartis Investigative Site

Palermo, PA, Italy, 90146

Actively Recruiting

7

Novartis Investigative Site

Roma, RM, Italy, 00161

Actively Recruiting

8

Novartis Investigative Site

Roma, RM, Italy, 00168

Actively Recruiting

9

Novartis Investigative Site

Torino, TO, Italy, 10126

Actively Recruiting

10

Novartis Investigative Site

Bassano del Grappa, VI, Italy, 36061

Actively Recruiting

Loading map...

Research Team

N

Novartis Pharmaceuticals

N

Novartis Pharmaceuticals

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

A Randomized, Double-Blind, Placebo-Controlled, First-In-Hum...

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Actively Recruiting

7 locations

An Open Label, Single-Arm, Phase 2 Study to Evaluate the Saf...

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Actively Recruiting

12 locations

Haplo-identical Transplantation Using Peripheral Blood Stem ...

Severe Aplastic Anemia (SAA)

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here